Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials-Reference-Cited by-同舟云学术

Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials

Published:2024-06-24 Issue: Volume: Page:
ISSN:0937-4477
Container-title:European Archives of Oto-Rhino-Laryngology
language:en
Short-container-title:Eur Arch Otorhinolaryngol

Author:

Wang Shuangyue,Huang Xiaojie,Li Rong,Zhou Ziyan,Kang Min^ORCID

Funder

the National Natural Science Foundation of China

Scientific Research and Technology Development Program of Guangxi Zhuang Autonomous Region

the Research Foundation of the Health Department of Guangxi Province

Guangxi Medical University Training Program for Distinguished Young Scholars

Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University

Guangxi Overseas High‐level Talent “Hundred People Program”

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00405-024-08768-w.pdf

Reference29 articles.

1. Chen Y-P, Chan ATC, Le Q-T et al (2019) Nasopharyngeal carcinoma. Lancet 394:64–80. https://doi.org/10.1016/S0140-6736(19)30956-0

2. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

3. Wong KCW, Hui EP, Lo K-W et al (2021) Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 18:679–695. https://doi.org/10.1038/s41571-021-00524-x

4. Zhang L, Huang Y, Hong S et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 388:1883–1892. https://doi.org/10.1016/S0140-6736(16)31388-5

5. Huang Z-L, Liu S, Wang G-N et al (2019) The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int 19:141. https://doi.org/10.1186/s12935-019-0863-5